Quantinno Capital Management LP Increases Stock Holdings in Amgen Inc. $AMGN

Quantinno Capital Management LP grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 17.7% during the first quarter, Holdings Channel reports. The firm owned 364,725 shares of the medical research company’s stock after purchasing an additional 54,742 shares during the period. Quantinno Capital Management LP’s holdings in Amgen were worth $128,329,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of AMGN. Vanguard Group Inc. grew its position in shares of Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after buying an additional 961,975 shares during the last quarter. State Street Corp raised its stake in Amgen by 4.4% during the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after acquiring an additional 1,287,310 shares in the last quarter. Capital World Investors lifted its position in Amgen by 22.9% in the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after acquiring an additional 4,302,237 shares during the last quarter. Geode Capital Management LLC lifted its position in Amgen by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after acquiring an additional 1,035,779 shares during the last quarter. Finally, Norges Bank purchased a new stake in Amgen in the fourth quarter valued at $2,164,162,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Weiss Ratings lowered Amgen from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, July 15th. UBS Group upped their target price on Amgen from $400.00 to $420.00 and gave the company a “buy” rating in a research report on Monday, July 13th. BMO Capital Markets restated an “outperform” rating and set a $400.00 price target on shares of Amgen in a research note on Wednesday, July 1st. Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Finally, Canaccord Genuity Group began coverage on Amgen in a research report on Monday, April 20th. They set a “hold” rating and a $366.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $356.62.

Amgen Trading Up 0.1%

Shares of Amgen stock opened at $376.26 on Tuesday. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $391.29. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The company’s 50-day simple moving average is $352.31 and its 200-day simple moving average is $352.35. The firm has a market cap of $203.07 billion, a price-to-earnings ratio of 26.18, a price-to-earnings-growth ratio of 3.80 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the company posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities research analysts anticipate that Amgen Inc. will post 22.31 earnings per share for the current year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.